3-(2-methyl-2-oxoethyl)-1,2-dimethylimidazolium chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-methyl-2-oxoethyl)-1,2-dimethylimidazolium chloride
• 英文别名: 1-(2,3-Dimethylimidazol-3-ium-1-yl)propan-2-one;chloride；1-(2,3-dimethylimidazol-3-ium-1-yl)propan-2-one;chloride
• 化学式: C₈H₁₃N₂O*Cl
• 分子量: 188.657
• InChiKey: KQNYYGPCYWZSKV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.79
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  吡啶 、 3-(2-methyl-2-oxoethyl)-1,2-dimethylimidazolium chloride 、 palladium dichloride 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以11%的产率得到
  参考文献：
  名称：

  Catalytic application of zwitterionic palladium complexes in Mizoroki–Heck reactions using ionic liquid as solvent

  摘要：

  New ligand precursors with different pendent alky chain length were obtained in a single step by reacting appropriate 1-alkyl-2-methyl-1H-imidazoles with chloroacetone in THF at 80 degrees C overnight. Zwitterionic palladium complexes were prepared by reacting PdCl2 with these new imidazole derivatives in DMF with the presence of pyridine and Cs2CO3 as base at room temperature for 5 h. These new compounds were characterized by H-1 and C-13{H-1} NMR spectroscopy, elemental analysis, and electrospray ionization mass spectrometry. They were effectively applied as recyclable catalysts for mediating Mizoroki-Heck reactions in ionic liquids. Transmission emission microscopy revealed that palladium nanoparticles were formed during the catalytic process. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2015.05.020
• 作为产物：
  描述：

  1,2-二甲基咪唑 、 一氯丙酮 以 四氢呋喃 为溶剂， 反应 24.0h， 以90%的产率得到3-(2-methyl-2-oxoethyl)-1,2-dimethylimidazolium chloride
  参考文献：
  名称：

  Catalytic application of zwitterionic palladium complexes in Mizoroki–Heck reactions using ionic liquid as solvent

  摘要：

  New ligand precursors with different pendent alky chain length were obtained in a single step by reacting appropriate 1-alkyl-2-methyl-1H-imidazoles with chloroacetone in THF at 80 degrees C overnight. Zwitterionic palladium complexes were prepared by reacting PdCl2 with these new imidazole derivatives in DMF with the presence of pyridine and Cs2CO3 as base at room temperature for 5 h. These new compounds were characterized by H-1 and C-13{H-1} NMR spectroscopy, elemental analysis, and electrospray ionization mass spectrometry. They were effectively applied as recyclable catalysts for mediating Mizoroki-Heck reactions in ionic liquids. Transmission emission microscopy revealed that palladium nanoparticles were formed during the catalytic process. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2015.05.020

文献信息

• Method for treating fibrotic diseases or other indications IC
  申请人：Alteon, Inc.

  公开号：US20020068729A1

  公开（公告）日：2002-06-06

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种处理、改善或预防动物包括人类发明的指示的方法，包括给予公式I的化合物的有效量：1
• Method for treating fibrotic diseases or other indications with imidazolium agents
  申请人：Alteon, Inc.

  公开号：US20030176426A1

  公开（公告）日：2003-09-18

  Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: 1 wherein R 1 , R 2 , M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

  提供了一种治疗或改善动物（包括人类）发明的征兆的方法，通过给予公式I的有效量的化合物： 1 其中R 1 ，R 2 ，M，X和Z如上所述。还提供了一些咪唑啉化合物和包含咪唑啉化合物的药物组合物。
• Method for treating fibrotic diseases or other indications ID
  申请人：——

  公开号：US20020177586A1

  公开（公告）日：2002-11-28

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种在动物中（包括人类）治疗、改善或预防本发明指示的方法，其中包括给予化合物I的有效量：1。
• Method for treating fibrotic diseases or other indications IE
  申请人：——

  公开号：US20040235837A1

  公开（公告）日：2004-11-25

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种治疗、改善或预防发明所示迹象的方法，在动物中包括人类，该方法包括给予化合物I的有效剂量：1。
• Method for treating glaucoma IC
  申请人：——

  公开号：US20020160993A1

  公开（公告）日：2002-10-31

  Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I: 1

  提供了一种治疗、改善或预防青光眼、降低眼压或改善或缓解动眼调节的方法，包括在动物（包括人类）中给予化合物I的降低眼压或改善动眼调节的剂量。